Harvard Medical School
哈佛医学院
Harvard Medical School is the institution where Chinese biotech investor Kan Chen of Qiming Venture Partners completed his postdoctoral training, following his undergraduate studies at Fudan University . In elsewhere's corpus, it also appears as a former affiliation for a participant in 5Y Capital's 3Sigma Bootcamp — a long-term professor at South China University of Technology who was previously a research professor at Harvard Medical School, with publications in *Nature* and *Cell* . The medical school is referenced in passing as part of career trajectories in China's life sciences and venture capital ecosystem rather than as a subject of direct reporting.
AI-generated — may contain errors, please verify.
Coverage
Qiming Venture Partners' Kan Chen: There's an Optimal Path for Chinese Innovative Drugs Going Global
Move beyond single concepts and invest in "global biotech."
3Sigma Bootcamp Application Countdown | Seeking Frontier Tech Founders Ready to Break the Paradigm
The essence of innovation is stepping outside the boundaries of established paradigms — even when that means a kind of madness others won't understand.
Li Feng in Conversation with Academician Shao Feng: New Trends in Drug Discovery
How Can Basic Research Better Connect with Industry in Biomedicine, a Field Where "the Barrier to Entry Is Low, but the Courtyard Runs Deep"?
